F/m Emerald Life Sciences Innovation ETF
LFSCETF · Nasdaq
$44.19
+$0.92 (+2.12%)
EOD Nov 3, 2026
Key facts
- Dividend yield (TTM)
- 0.00%
- Distributions
- Irregular
- Fund net assets (May 2026)
- $105M
- Stocks held
- 39
- Other positions
- 1
- 52-week range
- $31.02 to $48.78
Top 10 holdings
All holdings54.7% of assets in ten stocks, as of May 31, 2026
| Company | Weight | Quality |
|---|---|---|
| 7.67% | 52 | |
| 7.53% | 10 | |
| 7.11% | 67 | |
| 6.41% | 10 | |
| 5.52% | 30 | |
| 4.92% | 30 | |
| 4.79% | 56 | |
| 4.16% | 78 | |
| 3.42% | n/a | |
| 3.22% | 10 |
Sector allocation
Share of the fund's assets
- Healthcare95.6%
- Technology2.0%
- Industrials0.4%
Scores of what it owns
Every holding's scoreEach holding's score, weighted by its size in the fund
5% of the fund's stock weight sits in companies with a Quality score above 75, 57% in companies below 50.
Where it invests
Stock weight by the company's home country
- United States92.0%
- United Kingdom7.1%
- Singapore1.0%
Growth of $10,000
With and without the dividends reinvested
Dividend
Dividend historyLFSC has not paid a dividend in the last twelve months.
LFSC questions
What does LFSC invest in?+
F/m Emerald Life Sciences Innovation ETF is an exchange-traded fund. Its largest holdings are Travere Therapeutics Inc. (7.67%), Cogent Biosciences, Inc. (7.53%), LivaNova PLC (7.11%).
How good are the companies LFSC owns?+
Weighted by position size, the stocks in LFSC average a Quality score of 37 out of 100. 5% of the fund's stock weight sits in companies scoring above 75, 57% in companies below 50. The score is computed from each company's SEC filings; the methodology page lists every check.
Holdings: the fund's latest SEC Form N-PORT, as of May 31, 2026. Expense ratio, turnover and returns: the fund's shareholder report (SEC Form N-CSR) for the period to n/a. Net assets: SEC Form N-PORT. Quality scores: computed by Intrinsiqq from each company's SEC filings (methodology). Price: end of day Nov 3, 2026.